Curevo Vaccine Announces $26 Million Series A1 Financing to Support Clinical Development of Next-Generation Subunit Vaccines

-- Curevo’s lead program is CRV-101, an adjuvanted subunit vaccine for shingles, which has completed enrollment in a 678-patient Phase 2b head-to-head trial of CRV-101 against Shingrix® with data due early 2023 November 16, 2022 10:00 AM Eastern Standard Time SEATTLE--(BUSINESS WIRE)--Curevo Vaccine (Curevo), a privately held clinical-stage biotechnology company dedicated to reducing the burden of infectious disease by developing…

Curevo Vaccine Announces Enrollment Complete in Phase 2b Trial of CRV-101 Vaccine Against Shingles

-- Phase 2b trial enrolled 678 participants in six months -- Topline data from Phase 2b head-to-head trial of CRV‑101 against Shingrix® expected in early 2023 SEATTLE, Sept. 15, 2022 /PRNewswire/ -- Curevo Vaccine (Curevo), a privately held clinical-stage biotechnology company dedicated to reducing the burden of infectious disease by developing safe and highly-effective vaccines, today announced completion of enrollment in a Phase 2b trial of their CRV-101…

Vaccine startup Curevo takes on pharma giant GSK, raises $60M for trial of shingles shot

SEATTLE–(GEEKWIRE)–Curevo has raised $60 million to develop a new vaccine for shingles, an often-painful condition caused by reactivation of the chickenpox virus. The new funding will enable the Seattle-based startup to test its vaccine against a market-commanding shot made by GlaxoSmithKline. Curevo’s upcoming phase 2b trial will compare safety of the two vaccines in more than 650 people, and assess immune…

$60 Million Funding Supports Shingles Vaccine Candidate

(Precision Vaccinations) Washington-based Curevo Vaccine today announced the closing of a $60 million Series A financing round that would support the 678-patient Phase 2b head-to-head clinical trial of the CRV‑101 shingles vaccine candidate against Shingrix®, from initiation through topline data. CRV-101 is a clinical-stage adjuvanted sub-unit vaccine specifically designed to produce an optimal immune response while using a smaller amount of adjuvant with the intention of…

Curevo Vaccine Announces $60 Million Series A Financing to Support Clinical Development of Next Generation Subunit Vaccines

SEATTLE–(BUSINESS WIRE)–Curevo Vaccine (Curevo), a privately held clinical-stage biotechnology company dedicated to reducing the burden of infectious disease by developing safe and highly-effective vaccines, today announced the closing of a $60 million Series A financing round. “The upcoming Phase 2b trial is designed to compare CRV‑101’s immunogenicity and safety profile relative to Shingrix®. “I’m excited to close this financing and…

A small Seattle biotech wants to take on GlaxoSmithKline’s emerging Shingrix blockbuster. RA Capital is on board

GlaxoSmithKline’s Shingrix has quickly become one of the company’s best-selling products since first winning FDA approval in 2017. But a new biotech believes it can do better — and RA Capital is listening. Curevo Vaccine, a Seattle-based company, debuted a $60 million Series A on Thursday led by the prominent life sciences VC, aiming to fund a Phase IIb study…

Curevo Presenting at World Vaccine Conference Congress (Washington) Sept 28 – Oct 1

Curevo Vaccine’s Steve Reed, PhD, Scientific Advisory and Executive Board member, and Lisa Shelton, ARNP, Associated Director Clinical Operations,  will be presenting at World Vaccine Congress Wednesday, September 30 @ 4:50pm EST/1:50pm PST , on Low side-effect safety profile demonstrated in phase 1 trial of shingles vaccine candidate CRV-101.  Join us to hear about the safety and a sneak peek into the…

SAHPRA Approval Press Announcement 2021

CUREVO VACCINE ANNOUNCES THE APPROVAL TO CONDUCT A PHASE 1B CLINICAL TRIAL IN SOUTH AFRICA TO EVALUATE SAFETY AND IMMUNOGENICITY OF ITS ADJUVANTED SUBUNIT INVESTIGATIONAL VACCINE, CRV-101, AGAINST VARICELLA (CHICKENPOX) IN HIV-POSITIVE CHILDREN. Curevo Vaccine, a clinical-stage biopharmaceutical company combining excellence in protein and adjuvant biology to develop new generation sub-unit vaccines of global importance, announced today that approval was…

Curevo Vaccine Announces Robust Antibody Response Results of Phase I Clinical Trial of Investigational Vaccine for Shingles CRV-101

SEATTLE–(BUSINESS WIRE)–Curevo Vaccine, a clinical stage biopharmaceutical company developing next generation vaccines for patients with infectious disease of global importance, today announced antibody response data from its completed Phase 1 study investigating the safety, tolerability, and immune system response of CRV-101 in several formulations. The administration of Curevo’s adjuvanted sub-unit Shingles investigational vaccine resulted in a robust antibody response against…

Curevo Vaccine Announces Interim Results of Phase I Clinical Trial of CRV-101

SEATTLE–(BUSINESS WIRE)–Curevo, Inc., a Seattle-based biotechnology company invested in by GC Pharma, one of the largest therapeutic protein manufacturers in the world, has announced encouraging preliminary Phase I safety and tolerability results of their Shingles vaccine candidate, CRV-101. Interim trial results demonstrating a promising safety and tolerability profile of the vaccine in 90 healthy adults ≥18 to <50 were presented…